Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs
By Mariam Sunny Sept 14 (Reuters) - Eli Lilly on Monday said it has captured more than 30% of new patients in the U.S. market for oral obesity treatments, narrowing the early lead gained by Danish rival Novo Nordisk with its Wegovy pill.